Regular ArticleIfosfamide and Mesna in Epithelial Ovarian Carcinoma
References (0)
Cited by (16)
Epithelial ovarian cancer
2018, Clinical Gynecologic OncologyEpithelial Ovarian Cancer
2012, Clinical Gynecologic Oncology: Eighth EditionManagement of Recurrent Ovarian Carcinoma: Current Status and Future Directions
2009, Seminars in OncologyCitation Excerpt :The decision of whether and when to use oral etoposide is influenced by the degree of gastrointestinal complications caused by the patient's cancer as she must be able to tolerate oral therapy in order to have a chance of benefit from this agent. Vinorelbine,60-62 cyclophosphamide, ifosfamide,63,64 and melphalan65 also have been used to treat recurrent disease, with response rates ranging from 10% to 20%, and these drugs may be considered for those patients who have continued relative sensitivity to chemotherapy and have received the more commonly used agents. Hexamethylmelamine (RR, 10%-17%)66-71 is an oral agent that is approved for the treatment of patients with recurrent ovarian carcinoma, although its use is limited by gastrointestinal toxicity.
Epithelial Ovarian Cancer
2007, Clinical Gynecologic OncologySynthesis and evaluation of Taxol-folic acid conjugates as targeted antineoplastics
2002, Bioorganic and Medicinal ChemistryCitation Excerpt :The first two lines express high levels of the folate receptor.22 The A549 cell line, however, expresses negligible levels of functional folate receptors.23 With the exception of Taxol 14 being uniformly more potent, little difference was seen with respect to folate receptor involvement (Fig. 3).